DNA methylation biomarker in Crohn’s disease

IF 51 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-07-28 DOI:10.1038/s41575-025-01104-5

Katrina Ray

引用次数: 0

查看原文本刊更多论文

克罗恩病的DNA甲基化生物标志物

已经开发并验证了一种用于预测成人克罗恩病生物治疗反应的DNA甲基化生物标志物面板，该面板能够预测对vedolizumab和ustekinumab的反应，但不能预测对阿达木单抗的反应。纳入来自荷兰阿姆斯特丹的发现队列，计划在有活动性症状和内窥镜的克罗恩病患者中使用阿达木单抗、维多利单抗和乌斯特金单抗的成人（18岁）（n = 183）；n = 90，来自英国牛津的验证队列)。对治疗前采集的血液样本进行全表观基因组DNA甲基化和全转录组基因表达分析。治疗效果在中位28周后评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.